imkasid 2025 SEOUL. E-poster

검색
  • ALL
  • Poster Oral Presentation
    • G1: Basic / Translational / Microbiome
    • G2: IBD, Clinical
    • G3: IBD, Basic / Translational
    • G4: Colorectal Neoplasia, Clinical
    • G5: Colorectal Neoplasia, Basic / Translational
    • G6: Small Bowel Disease / Nutrition / Functional disorder
    • G7: AI / Others
  • Poster Exhibition
    • G1: Basic / Translational / Microbiome
    • G2: IBD, Clinical
    • G3: IBD, Basic / Translational
    • G4: Colorectal Neoplasia, Clinical
    • G5: Colorectal Neoplasia, Basic / Translational
    • G6: Small Bowel Disease / Nutrition / Functional disorder
    • G7: AI / Others
    • G8: [New] IBD, Clinical, Trial Encore Submission
  • PE8-01 Poster Exhibition

    View : 6
    Efficacy and Safety of Obefazimod in UC Patients at Week 48 of an Open-label Maintenance Study among Clinical Non-responders at Week 8 of the Phase 2b Induction Trial

    Presenting Author : Raja Atreya (University Hospital Erlangen, Germany)

  • PE8-02 Poster Exhibition

    View : 9
    Efficacy and Safety of Etrasimod Induction Therapy in Asia Patients with Moderately to Severely Active Ulcerative Colitis: Results from the 12-week Induction Period of Phase 3 China Registrational Study (ES101002)

    Presenting Author : Tae-Oh Kim (Inje University Haeundae Paik Hospital, Korea)

  • PE8-03 Poster Exhibition

    View : 9
    Measurement of IL-6, IL-6Ra and GP130 in Gastrointestinal Behcet Disease Mucosal Biopsies

    Presenting Author : Philippe Pinton (Ferring Pharmaceuticals, Denmark)

  • PE8-04 Poster Exhibition

    View : 7
    Improvements in Inflammatory Bowel Disease Questionnaire Items Fatigue, Depression, Anxiety, and Bowel Urgency in Patients with Crohn's Disease Treated With Upadacitinib in Phase 3 Trials

    Presenting Author : Scott Choi (AbbVie Korea, Korea)

  • PE8-05 Poster Exhibition

    View : 1
    Improvement in Health-Related Quality of Life in Adults with Recurrent Clostridioides difficile Infection after Fecal Microbiota, Live-jslm (RBX2660) Administration by Colonoscopy

    Presenting Author : Philippe Pinton (Ferring Pharmaceuticals, A/S, Denmark)

  • PE8-06 Poster Exhibition

    View : 16
    Budget lmpact Analysis to Assess Potential Cost Savings from the lntroduction of Ustekinumab Biosimilars in Germany, the UK, and Sweden

    Presenting Author : Joungyoun Noh (Samsung Bioepis, Korea)

  • PE8-07 Poster Exhibition

    View : 9
    TUSCANY-2: A Dose-Ranging Phase IIb Study Evaluating Efficacy and Safety of RO7790121, an Antibody Against Tumor Necrosis Factor-like Ligand 1A (Anti-TL1A) in Adults with Moderately to Severely Active Ulcerative Colitis

    Presenting Author : Eun Soo Kim (School of Medicine, Kyungpook National University, Korea)

  • PE8-08 Poster Exhibition

    View : 7
    Efficacy and Safety of Upadacitinib after 3 years of Treatment in Patients with Moderately to Severely Active Ulcerative Colitis: Interim Long-term Data from the Phase 3 Open-label Extension Study

    Presenting Author : Scott Choi (AbbVie Korea, Korea)

  • PE8-09 Poster Exhibition

    View : 6
    Corticosteroid-free Clinical and Endoscopic Response of Risankizumab Through Week 144 in Patients With Moderately to Severely Active Crohn’s Disease: A Post hoc Analysis from the fortify Long-term Extension Substudy

    Presenting Author : Scott Choi (AbbVie Korea, Korea)

  • PE8-10 Poster Exhibition

    View : 10
    Support Program for Patients Receiving Imraldi or Benepali Therapy for Immune-mediated Inflammatory Disorders: 12-Month Persistence

    Presenting Author : Andrew Clark (Biogen Idec Ltd., United Kingdom)

  • PE8-11 Poster Exhibition

    View : 9
    Persistence of Treatment Effect in Patients with Ulcerative Colitis and Crohn’s Disease: Long-term Results from the Visible Ole Study

    Presenting Author : Dong Il Park (Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University, Korea)

  • PE8-12 Poster Exhibition

    View : 2
    Management of Recurrent Clostridioides Difficile Infection: A Systematic Literature Review to Assess the Feasibility of Indirect Treatment Comparisons

    Presenting Author : Philippe Pinton (Ferring Pharmaceuticals, A/S, Denmark)

  • PE8-13 Poster Exhibition

    View : 14
    Real-world Safety and Effectiveness of SB5 (adalimumab biosimilar) in South Korea: A Real-world Post-marketing Surveillance Interim Analysis Data

    Presenting Author : Hawon Jeong (Samsung Bioepis, Korea)

  • 처음
  • 이전
  • 1
  • 다음
  • 마지막